admin

admin

Novartis Ends BioArctic Brain Delivery Program

BioArctic disclosed at 21:30 CET on November 2 that Novartis will terminate the companies’ August 2025 option, collaboration, and license agreement for an undisclosed antibody using BioArctic’s transferrin-receptor BrainTransporter delivery technology. This is a…

CTX310 Receives Two FDA RMAT Designations

In a November 2 disclosure recovered in the 36-hour window, CRISPR Therapeutics said FDA granted Regenerative Medicine Advanced Therapy (RMAT) designations to CTX310 for severe hypertriglyceridemia and elevated LDL-C. The company also reported third-quarter…